Histology → first-line choice in mesothelioma
Read the tumour type under the microscope first: non-epithelioid tumours should get immunotherapy up front; epithelioid tumours can reasonably get either immunotherapy or chemo-immunotherapy.
In non-epithelioid disease nivolumab-ipilimumab roughly doubled median OS versus chemotherapy (18.1 vs 8.8 months); in epithelioid disease the difference was small (18.7 vs 16.5). Pembrolizumab-chemotherapy showed the same pattern. Guidelines now stratify by histology.
Pages like this
not linked directly; found by shared links- TrialBEAT-meso (ETOP 13-18)
Shares Epithelioid vs sarcomatoid (biphasic) mesothelioma, Pemetrexed, Mesothelioma.
- PersonSolange Peters
Shares CheckMate 743, Ipilimumab, Mesothelioma, Nivolumab.
- TermImmune-related endocrinopathies (thyroiditis, hypophysitis)
Shares Ipilimumab, Nivolumab, Pembrolizumab, Immune checkpoint inhibitors.
- TrialDREAM3R
Shares Pemetrexed, Mesothelioma.
- TrialLUME-Meso
Shares Pemetrexed, Mesothelioma.
- TrialMAPS
Shares Pemetrexed, Mesothelioma.
- IdeaSubscription pricing for checkpoint inhibitors: fixed national fee, unlimited use
Shares Nivolumab, Pembrolizumab, Immune checkpoint inhibitors.
- TrialKEYNOTE-006
Shares Ipilimumab, Pembrolizumab, Immune checkpoint inhibitors.